Randomized Comparison of Doxorubicin Alone Versus Ifosfamide Plus Doxorubicin or Mitomycin, Doxorubicin, and Cisplatin Against Advanced Soft Tissue Sarcomas
Overview
Affiliations
Purpose: This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin.
Patients And Methods: Between December 1987 and July 1990, 279 patients with histologically confirmed sarcomas were enrolled to receive treatment A (doxorubicin 80 mg/m2), treatment B (ifosfamide 7.5 g/m2 plus doxorubicin 60 mg/m2), or treatment C (mitomycin 8 mg/m2 plus doxorubicin 40 mg/m2 plus cisplatin 60 mg/m2).
Results: Of 262 assessable patients, 74 (29%) achieved objective tumor regression. Objective regression occurred in 20% of the 90 patients who received doxorubicin alone (complete remission [CR] rate, 2%), in 34% of the 88 who received ifosfamide plus doxorubicin (CR rate, 3%), and in 32% of the 84 who received mitomycin plus doxorubicin plus cisplatin (CR rate, 7%). With grade 3 or greater myelosuppression in 53% of group A, 80% of group B, and 55% of group C, regimen B was significantly more myelosuppressive than either regimen A or C (P = .01) with two, three, and one treatment-related deaths, respectively. Synovial sarcomas were responsive to ifosfamide plus doxorubicin, especially among patients younger than 40 years of age.
Conclusion: Ifosfamide plus doxorubicin produced a significantly higher regression rate (P = .03) than did doxorubicin alone; however, this was achieved at a level of myelosuppression significantly more intense than that produced by the single agent or by the three-drug combination. Mitomycin, doxorubicin, and cisplatin also appeared to be more active than the single agent; however, at a myelosuppression level similar to that of doxorubicin alone, this trend (P = .07) did not attain the usual level for significance. No significant survival differences were observed.
Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?.
Paudel A, Chattopadhyay P, Rose B, Watson A, DAmato G, Trent J Cancers (Basel). 2025; 17(5).
PMID: 40075735 PMC: 11898467. DOI: 10.3390/cancers17050889.
Primary Mediastinal Synovial Sarcoma with Pericardial Involvement: A Case Report.
Michaels K, Dougherty S, Kurpiel B, Douvas M Case Rep Oncol. 2025; 18(1):76-84.
PMID: 39980501 PMC: 11731899. DOI: 10.1159/000542680.
Skorka P, Kordykiewicz D, Ilkow A, Ptaszynski K, Wojcik J, Skorka W Life (Basel). 2025; 14(12.
PMID: 39768355 PMC: 11680011. DOI: 10.3390/life14121648.
Xu B, Pan Q, Pan H, Li H, Li X, Chen J EClinicalMedicine. 2023; 64:102240.
PMID: 37767191 PMC: 10520347. DOI: 10.1016/j.eclinm.2023.102240.
Inoguchi Y, Hatano K, Kato T, Kawashima A, Abe T, Fukuhara S Int Cancer Conf J. 2023; 12(2):115-119.
PMID: 36896201 PMC: 9989117. DOI: 10.1007/s13691-022-00589-0.